Drug Trial Radar · NCT06069544
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
163
Actual
Start
Nov 13, 2023
Primary completion
May 28, 2025
Study completion Mar 20, 2026
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a randomized, dose-escalation Phase I/IIa study to evaluate safety, tolerability, immunogenicity and efficacy of an investigational RNA-based vaccine (BNT165e) for prevention of P. falciparum malaria in healthy malaria-naive adults. The multi-antigen malaria vaccine (designated BNT165e) is a combination of three distinct RNAs, BNT165c and BNT165d (composed of BNT165d1 and BNT165d2), encoding P. falciparum antigens encapsulated in lipid nanoparticles. The BNT165c RNA encodes the full Plasmodium falciparum circumsporozoite protein. The BNT165d1 and BNT165d2 RNAs both encode conserved, immunogenic segments of liver stage-expressed proteins.
Conditions
- Malaria
Interventions
BNT165cBiological
Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection
BNT165dBiological
Multi-antigen RNA-based vaccine for active immunization against malaria administered as intramuscular injection
PlaceboOther
Isotonic NaCl solution (0.9%)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and Percentage of Participants With Solicited Local Reactions at the Injection SiteTime frame: Up to 7 days after each IMP dose, (i.e., post-Dose 1, post-Dose 2, and post-Dose 3)
- Number and Percentage of Participants With Solicited Systemic ReactionsTime frame: Up to 7 days after each IMP dose, (i.e., post-Dose 1, post-Dose 2, and post-Dose 3)
- Number of Participants With at Least One Adverse Event (AE)Time frame: From administration of each IMP dose (i.e., Dose 1, Dose 2, and Dose 3) up to 28 days after the respective IMP dose
- Number of Participants With at Least One Medically Attended Adverse Event (MAAE)Time frame: From Dose 1 up to 24 weeks after last received IMP dose, up to 13 months.
- Number of Participants With at Least One Serious Adverse Event (SAE)Time frame: From Dose 1 up to 24 weeks after last received IMP dose, up to 13 months.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
AMR Tempe
Tempe, Arizona
University of Maryland, Center for Vaccine Development
Baltimore, Maryland
AMR Las Vegas
Las Vegas, Nevada
AMR Knoxville
Knoxville, Tennessee
Clinical Trials of Texas
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.